Last searches
Results for *
Displaying results 1 to 25 of 50.
-
Manufacturing for export
a TRIPS-consistent pro-competitive exception -
Twenty years after Doha
an analysis of the use of the TRIPS Agreement's public health flexibilities in India -
The human right to science
from fragmentation to comprehensive implementation? -
Brazilian competition law and access to health in Brazil
exploitative pricing in the pharmaceutical sector -
Lessons from India's implementation of Doha Declaration on TRIPS and Public Health
-
¿Podrán las negociaciones en la organización mundial de la salud resultar en un marco justo para la prevención, la preparación y la respuesta ante pandemias como bienes públicos globales?
-
Les négociations au sein de l'Organisation mondiale de la santé peuvent-elles aboutir à un cadre juste pour la prévention, la préparation et la riposte aux pandémies en tant que bien public mondial?
-
Can negotiations at the World Health Organization lead to a just framework for the prevention, preparedness and response to pandemics as global public goods?
-
An examination of selected public health exceptions in Asian patent laws
-
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
-
TRIPS flexibilities and access to medicines
an evaluation of barriers to employing compulsory licenses for patented pharmaceuticals at the WTO -
Left on our own
COVID-19, TRIPS-Plus Free Trade Agreements, and the Doha Declaration on TRIPS and Public Health -
Pautas para el examen de solicitudes de patentes relacionadas con productos farmacéuticos
-
The TRIPS Agreement Article 73 Security Exceptions and the COVID-19 pandemic
-
Special Section 301: US interference with the design and implementation of national patent laws
-
Equitable access to COVID-19 related health technologies
a global priority -
Non-violation and situation complaints under the TRIPS Agreement
implications for developing countries -
Guide for the granting of compulsory licenses and government use of pharmaceutical patents
-
Guía para la concesión de licencias obligatorias y uso gubernamental de patentes farmacéuticas
-
The comprehensive and progressive agreement for the trans-pacific partnership
data exclusivity and access to biologics -
Intersección entre competencia y patentes
hacia un ejercicio pro-competitivo de los derechos de patente en el sector farmacéutico -
Eighteen years after Doha
an analysis of the use of public health TRIPS flexibilities in Africa -
Direito brasileiro da concorrência e acesso à saúde no Brasil
preços exploratórios no setor de medicamentos -
Neglected dimension of the inventive step as applied to pharmaceutical and biotechnological products
the case of Sri Lanka's patent law -
TRIPS flexibilities and TRIPS-plus provisions in the RCEP chapter on intellectual property: how much policy space is retained?